Table 12.

High risk melanomas: adjuvant treatment with low and intermediate dose interferon.

Trial	No. of cases	SLE	OS
Low dose IFN (3 mU × 3/s × 3 y.):
WHO-16 (Cascinelli et al.2001) [47]	426	NS	NS
UK [48]	674	NS	NS
Scottish study (2001) [49]**	59	NS	NS
Ultralow dose IFN (1 mU):
EORTC/DKG-80 (Eggermont. 2001) [50]	830	NS	NS
Low dose INF + Isotretinoin (IFN: 3 mU × 3/s × 2 y.)
ECAMTSG ([51])	407	NS	NS
Intermediate dose IFN.
EORTC 18952*	1388	NS	NS
(10 mill. 13 m versus 5 mill. 25 m. versus observation)

Eggermont et al. Semin. Oncol. Spanish Ed. 3, 221–227, 2003*.

Hancock et al. J. Clin. Oncol. 22, 53–61, 2004 [48].

Cameron et al. BJC. 84(9): 1146–1149, 2001**

Richtig et al. JCO. 23, 34, 2005 [51].